MAIA Biotechnology, Inc.
$1.41
▼
-0.75%
2026-04-21 08:01:01
maiabiotech.com
ASE: MAIA
Explore MAIA Biotechnology, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$81.91 M
Current Price
$1.41
52W High / Low
$3.19 / $0.87
Stock P/E
—
Book Value
$0.06
Dividend Yield
—
ROCE
-618.06%
ROE
-7.45%
Face Value
—
EPS
$-0.7
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
13
Beta
0.32
Debt / Equity
—
Current Ratio
1.66
Quick Ratio
1.66
Forward P/E
0.47
Price / Sales
—
Enterprise Value
$69 M
EV / EBITDA
—
EV / Revenue
—
Rating
Strong Buy
Target Price
$12.13
EPS Forecast (FY)
—
Pros
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Lexeo Therapeutics, Inc. | $6.53 | — | $511.94 M | — | -85.23% | -55% | $10.99 / $2.19 | $3.38 |
| 2. | Agios Pharmaceuticals, Inc. | $27.07 | — | $1.54 B | — | -38.86% | -30.2% | $46 / $22.24 | $20.41 |
| 3. | Actuate Therapeutics, Inc. Common stock | $2.62 | — | $54.77 M | — | -270.08% | -5.54% | $11.99 / $1.58 | $0.34 |
| 4. | Generate Biomedicines, Inc. | $12.12 | — | $1.59 B | — | -94.79% | -81.72% | $15.32 / $11 | $-12.24 |
| 5. | Immunovant, Inc. | $28.53 | — | $5.81 B | — | -61.93% | -69.35% | $29.48 / $13.36 | $4.85 |
| 6. | 60 Degrees Pharmaceuticals, Inc. | $1.84 | — | $4.69 M | — | -220.2% | -2.01% | $17.68 / $1.29 | $-5.25 |
| 7. | INmune Bio Inc. | $1.49 | — | $39.61 M | — | -128.97% | -1.65% | $11.64 / $1.09 | $0.89 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M | 0 M | — |
| Operating Profit | -3.96 M | -9.36 M | -5.17 M | -5.43 M | -4.98 M | — |
| Net Profit | -3.63 M | -8.9 M | -5.35 M | -4.52 M | -3.57 M | — |
| EPS in Rs | -0.06 | -0.15 | -0.09 | -0.07 | -0.06 | -0.11 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M |
| Operating Profit | -23.91 M | -16.88 M | -20.01 M | -15.86 M |
| Net Profit | -22.4 M | -23.25 M | -19.77 M | -15.77 M |
| EPS in Rs | -0.37 | -0.38 | -0.33 | -0.26 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 9.7 M | 10.16 M | 7.57 M | 12.02 M |
| Total Liabilities | 7.33 M | 6.52 M | 7.09 M | 3.51 M |
| Equity | 2.38 M | 3.63 M | 0.48 M | 8.51 M |
| Current Assets | 9.7 M | 10.15 M | 7.56 M | 11.81 M |
| Current Liabilities | 5.84 M | 3.83 M | 4.94 M | 3.27 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -18.84 M | -15.7 M | -13.07 M | -12.1 M |
| Investing CF | — | — | — | — |
| Financing CF | 17.91 M | 18.18 M | 9.27 M | 12.48 M |
| Free CF | -18.84 M | -15.7 M | -13.07 M | -12.1 M |
| Capex | — | — | — | — |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | — | — | — | — |
| Earnings Growth % | -17.61% | -25.39% | — | — |
| Profit Margin % | — | — | — | — |
| Operating Margin % | — | — | — | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | — | — | — | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.